Androgen deficiency in aging men

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 3, 2006, Pages 254-261

  T'Sjoen, Guy G ^a   Kaufman, Jean Marc ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Aging; Androgen; Elderly; Male; Testosterone

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; PRASTERONE; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

AGING; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ATHEROSCLEROSIS; BODY COMPOSITION; BONE METABOLISM; CARDIOVASCULAR RISK; COGNITION; CORONARY ARTERY DISEASE; DEPRESSION; ERYTHROPOIESIS; HUMAN; HYPOGONADISM; MALE; MOOD; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SENILE OSTEOPOROSIS; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL;

EID: 33646692010     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000224805.31695.6a     Document Type: Review

References (85)

1. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26:833-876. A detailed review paper on sex steroids in elderly men, clinical significance of the decrease in androgen levels, diagnosis of ADAM and androgen treatment.
2. Tariq SH, Haren MT, Kim MJ, Morley JE. Andropause: is the emperor wearing any clothes? Rev Endocr Metab Disord 2005; 6:77-84. This excellent review points out the need for a large study to clearly define the positive and negative effects of testosterone in older males.
3. Snyder PJ. Hypogonadism in elderly men: what to do until the evidence comes. N Engl J Med 2004; 350:440-442.
4. Liu PY, Swerdloff RS, Veldhuis JD. Clinical review 171: The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab 2004; 89: 4789-4796.
5. Liu PY, Swerdloff RS, Wang C. Relative testosterone deficiency in older men: clinical definition and presentation. Endocrinol Metab Clin North Am 2005; 34:957-972.
6. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005; 90:678-688. A randomized, double-blind study with healthy, eugonadal 60-75-year-old men treated with a long-acting GnRH agonist and weekly injections of testosterone enanthate 25-600 mg.
7. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Andrology 2005; 28:125-127.
8. Tancredi A, Reginster JY, Luyckx F, Legros JJ. No major month to month variation in free testosterone levels in aging males: minor impact on the biological diagnosis of 'andropause'. Psychoneuroendocrinology 2005; 30:638-646.
9. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 2003; 26:76-83.
10. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 2004; 89:5898-5907.
11. Leder BZ, Rohrer JL, Rubin SD, et al. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 2004; 89:1174-1180.
12. Dougherty RH, Rohrer JL, Hayden D, et al. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. Clin Endocrinol (Oxf) 2005; 62:228-235. Thirty-seven men (62-74 years) with mild hypogonadism were randomized to receive either anastrozole 1 mg daily, anastrozole 1 mg twice weekly, or daily placebo for 12 weeks.
13. T'Sjoen GG, Giagulli VA, Delva H, et al. Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. J Clin Endocrinol Metab 2005; 90:5717-5722. The effect of letrozole, an aromatase inhibitor, on androgens and gonadotrophins was compared in young and older men.
14. Christ-Crain M, Meier C, Huber PR, et al. Value of gonadotropin-releasing hormone testing in the differential diagnosis of androgen deficiency in elderly men. J Clin Endocrinol Metab 2005; 90:1280-1286. This was a study on GnRH testing and luteinizing hormone response to differentiate PADAM from secondary hypogonadism.
15. Liu PY, Takahashi PY, Roebuck PD, et al. Aging in healthy men impairs recombinant human luteinizing hormone (LH)-stimulated testosterone secretion monitored under a two-day intravenous pulsatile LH clamp. J Clin Endocrinol Metab 2005; 90:5544-5550. Comparison between healthy older and young men in assessing testosterone secretion in response to near physiological luteinizing hormone stimulation.
16. Veldhuis JD, Keenan DM, Iranmanesh A. Mechanisms of ensemble failure of the male gonadal axis in aging. J Endocrinol Invest 2005; 28:8-13. A summary of recent clinical experiments of multisite failure of the male gonadal axis.
17. Morley JE, Perry HM 3rd, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2005. [Epub ahead of print] A comparison of three aging male questionnaires in 148 males aged 23-80 years.
18. Tancredi A, Reginster JY, Schleich F, et al. Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol 2004; 151:355-360.
19. Lin YC, Hwang TI, Chiang HS. Correlations of androgen deficiency with clinical symptoms in Taiwanese males. Int J Impot Res 2005. [Epub ahead of print]
20. Haren M, Chapman I, Coates P, et al. Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age Ageing 2005; 34:125-130. This paper describes a randomized, double-blind study with 80 mg oral T undecanoate twice daily or placebo in symptomatic elderly men.
21. Mäkinen J, Järvisalo MJ, Pöllänen P, et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 2005; 17;45:1603-1608. This study in middle-aged men (40-70 years) examined the association between carotid artery intima-media thickness and serum sex hormone levels.
22. Moore C, Huebler D, Zimmermann T, et al. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46:80-87.
23. Basar MM, Aydin G, Mert HC, et al. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology 2005; 66:597-601. Three hundred and forty-eight men (mean age 48.9 years) completed AMS and IIEF questionnaires and hormonal analysis were performed.
24. Tsujimura A, Matsumiya K, Miyagawa Y, et al. Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int J Impot Res 2005; 17:259-263.
25. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000; 53:703-711.
26. Heinemann LA, Zimmerman T, Vermeulen A, et al. A new 'aging males' symptoms rating scale. Aging Male 1999; 2:105-114.
27. Mahmoud AM, Goemaere S, El-Garem Y, et al. Testicular volume in relation to hormonal indices of gonadal function in community-dwelling elderly men. J Clin Endocrinol Metab 2003; 88:179-184.
28. Mohr BA, Guay AT, O'Donnell AB, McKinlay JB. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2005; 62:64-73. This paper contains new data from the Massachusetts Male Ageing Study, focusing on age-specific, normal androgen levels for men aged 40-79 years.
29. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89:5920-5926.
30. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89:3813-3817.
31. Schubert M, Minneman T, Hubler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89:5429-5434.
32. Korbonits M, Slawik M, Cullen D, et al. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 2004; 89:2039-2043.
33. Wang C, Swerdloff RS. Practical aspects of testosterone substitution. J Endocrinol Invest 2005; 28:109-111.
34. Barqawi A, Crawford ED. Testosterone replacement therapy and the risk of prostate cancer. Is there a link? Int J Impot Res 2005. [Epub ahead of print]
35. Wyllie MG. Andropause on the move? BJU Int 2005; 95:671-672.
36. Liu PY, Wishart SM, Celermajer DS, et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 2003; 148:55-66.
37. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocr Rev 2004; 25:389-425.
38. Barrett-Connor E, Bhasin S. Time for (more research on) testosterone. J Clin Endocrinol Metab 2004; 89:501-502.
39. Goderie-Plomp HW, van der Klift M, de Ronde W, et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab 2004; 89:3261-3269.
40. Handelsman DJ, Liu PY. Andropause: invention, prevention, rejuvenation. Trends Endocrinol Metab 2005; 16:39-45. This review focuses on the questionable basis for using androgen therapy to improve reproductive health in aging men.
41. Gennari L, Masi L, Merlotti D, et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004; 89:2803-2810.
42. Van Pottelbergh I, Goemaere S, Kaufman JM. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 2003; 88:3075-3081.
43. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503-510.
44. Crawford BA, Liu PY, Kean MT, et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88:3167-3176.
45. Aminorroaya A, Kelleher S, Conway AJ, et al. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol 2005; 152:881-886. This study describes a retrospective study of DEXA in men (22-84 years) with androgen deficiency requiring androgen replacement therapy.
46. Moretti C, Frajese GV, Guccione L, et al. Androgens and body composition in the aging male. J Endocrinol Invest 2005; 28:56-64. This is a review on mechanisms through which testosterone affects adipose tissue, muscle and bone.
47. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27:1036-1041.
48. Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005; 90:712-719. A prospective population-based study in initially middle aged men (42-60 years) to assess whether the metabolic syndrome predicts development of hypogonadism 11 years later.
49. Adamczak M, Rzepka E, Chudek J, Wiecek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol (Oxf) 2005; 62:114-118. The authors describe changes in adiponectin concentration with age in healthy females and males (20-93 years).
50. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 2004; 60:500-507.
51. Niskanen L, Laaksonen DE, Punnonen K, et al. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6:208-215.
52. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63:239-250. Review paper on testosterone as regulator of insulin sensitivity in men.
53. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90:1502-1510. In this elegant study hypogonadal men ≥65 years were randomly assigned to receive testosterone enanthate or placebo, with finasteride or placebo.
54. Schroeder ET, Zheng L, Ong MD, et al. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 2004; 89:4863-4872.
55. Sullivan DH, Roberson PK, Johnson LE, et al. Effects of muscle strength training and testosterone in frail elderly males. Med Sci Sports Exerc 2005; 37:1664-1672. This study determined the independent and combined effects of progressive resistance muscle strength training and testosterone on strength, muscle mass, and function in hypogonadal elderly males.
56. O'Donnell AB, Travison TG, Harris SS, et al. Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2006; 91:425-431.
57. Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004; 109:2074-2079.
58. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350:482-492.
59. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003; 24:313-340.
60. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24:183-217.
61. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89:3313-3318.
62. Maggio M, Basaria S, Ble A, et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab 2006; 91:345-347.
63. Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27:57-64. The authors describe testosterone replacement at physiological doses or placebo in 76 men (mean age 64 years) of which 24% were hypogonadal with heart failure over a maximum follow-up period of 12 months.
64. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 2003; 51:101-115.
65. Seftel AD, Mack RJ, Secrest AR, Smith TM. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl 2004; 25:963-972.
66. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (Andro-Gel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89:2085-2098.
67. Rhoden EL, Teloken C, Sogari PR, Souto CA. The relationship of serum testosterone to erectile function in normal aging men. J Urol 2002; 167:1745-1748.
68. Carosa E, Martini P, Brandetti F, et al. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf) 2004; 61:382-386.
69. Rochira V, Balestrieri A, Madeo B, et al. Sildenafil improves sleep-related erections in hypogonadal men: evidences from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J Androl 2006; 27:165-175. An evaluation of the effects of sildenafil on sleep-related erections in hypogonadal men and control subjects before and during testosterone replacement treatment.
70. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172:658-663.
71. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005; 63:381-394. This meta-analysis of available studies indicates that treatment with testosterone might be beneficial for improving vasculogenis erectile dysfunction in subjects with low or low-normal testosterone levels.
72. Gray PB, Singh AB, Woodhouse LJ, et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 2005; 90:3838-3846. The effects of graded testosterone doses on sexual function, mood and visuospatial cognition in healthy older men (60-75 years) are described in this well designed study.
73. Liu PY, Yee B, Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 2003; 88:3605-3613.
74. Muller M, Aleman A, Grobbee DE, et al. Endogenous sex hormone levels and cognitive function in aging men: is there an optimal level? Neurology 2005; 8:866-871.
75. Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology 2004 27;62:188-193.
76. Lessov-Schlaggar CN, Reed T, Swan GE, et al. Association of sex steroid hormones with brain morphology and cognition in healthy elderly men. Neurology 2005; 65:1591-1596. This study examined the predictive value of midlife total serum concentrations of testosterone, estradiol, estrone, and SHBG on cognitive task performance and regional brain volumes, in a longitudinal sample of World War II veteran twin men, at 10-1 6-year follow-up.
77. Cherrier MM, Plymate S, Mohan S, et al. Relationship between testosterone supplementation and insulin-like growth factor-I levels and cognition in healthy older men. Psychoneuroendocrinology 2004; 29:65-82.
78. Kenny AM, Fabregas G, Song C, et al. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci 2004; 59:75-78.
79. Cherrier MM, Matsumoto AM, Amory JK, et al. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 2005; 64:290-296. A randomized, double-blind, placebo-controlled study in 60 healthy men (50-90 years) with administration of testosterone enanthate, an aromatase inhibitor or placebo.
80. Hogervorst F, Bandelow S, Moffat SD. Increasing testosterone levels and effects on cognitive functions in elderly men and women. Curr Drug Targets CNS Neurol Disord 2005; 4:531-540. This review paper summarizes small-scale testosterone intervention trials and the effect on cognition in elderly men.
81. T'Sjoen G, De Vos S, Goemaere S, et al. Sex steroid level, androgen receptor polymorphism, and depressive symptoms in healthy elderly men. J Am Geriatr Doc 2005; 53:636-642. An observational study on the relationship between sex steroid status and a 30-item Geriatric Depression Scale score.
82. Shores MM, Moceri VM, Sloan KL, et al. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry 2005; 66:7-14.
83. Shores MM, Sloan KL, Matsumoto AM, et al. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 2004; 61:162-167.
84. Almeida OP, Waterreus A, Spry N, et al. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004; 29:1071-1081.
85. Morales A. Monitoring androgen replacement therapy: testosterone and prostate safety. J Endocrinol Invest 2005; 28:122-127. Recommendations for the safe use of testosterone in aging men.